Alkem Laboratories' Q1 FY 2025-26 Quarterly Results

Result Summary

• Alkem Laboratories Ltd reported a 16.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.3%.
• Its expenses for the quarter were up by 4.0% QoQ and 8.6% YoY.
• The net profit increased 119.4% QoQ and increased 21.4% YoY.
• The earnings per share (EPS) of Alkem Laboratories Ltd stood at 55.6 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alkem Laboratories Ltd is a prominent pharmaceutical company, primarily engaged in the development, manufacture, and sale of pharmaceutical products. It operates in the healthcare industry, focusing on both prescription medications and over-the-counter products. Alkem is known for its extensive portfolio of products, including formulations in various therapeutic segments such as anti-infectives, gastroenterology, pain management, and vitamins/minerals/nutrients. The company has a significant presence both in domestic and international markets, with a strong emphasis on research and development to drive innovation. As of the latest data, there are no specific recent major developments available for Alkem Laboratories Ltd.

Revenue

In Q1FY26, Alkem Laboratories Ltd reported a total income of ₹3507.63 crores, marking a 16.0% increase from the previous quarter's (Q4FY25) total income of ₹3023.99 crores. Compared to the same quarter of the previous fiscal year (Q1FY25), the total income rose by 11.3%, up from ₹3152.13 crores. The quarter-over-quarter growth indicates a significant rise in revenue generation, reflecting an upward trend in the company's financial performance over the last quarter. The year-over-year increase also demonstrates consistent growth in revenue streams, suggesting a positive trajectory in Alkem's market operations.

Profitability

Alkem Laboratories Ltd's profitability metrics show a robust performance in the latest quarter. The profit before tax (PBT) for Q1FY26 stood at ₹771.01 crores, which is a substantial increase of 109.9% from the previous quarter's PBT of ₹367.34 crores. Year-over-year, the PBT surged by 24.5% compared to ₹619.36 crores in Q1FY25. The company’s profit after tax (PAT) for Q1FY26 was ₹667.91 crores, reflecting a 119.4% growth over the last quarter's PAT of ₹304.48 crores and a 21.4% rise from the previous year's Q1 PAT of ₹550.24 crores. The earnings per share (EPS) also increased to ₹55.60 in Q1FY26, compared to ₹24.60 in the previous quarter and ₹45.60 in Q1FY25, with QoQ and YoY growth rates of 126.0% and 21.9% respectively.

Operating Metrics

The total expenses for Alkem Laboratories Ltd in Q1FY26 were reported at ₹2749.55 crores, which is a 4.0% increase from the previous quarter's expenses of ₹2644.13 crores. Year-over-year, the expenses increased by 8.6% from ₹2532.77 crores in Q1FY25. The company's tax expenses for Q1FY26 amounted to ₹102.69 crores, marking a 63.4% rise from Q4FY25's tax expenses of ₹62.86 crores and a 48.6% increase compared to the same quarter in the previous year, which was ₹69.12 crores. These figures reflect the overall cost and tax burden faced by Alkem Laboratories, showcasing the financial dynamics that contribute to its net income and operational efficiency across quarters.